Table 1.
Comparison of treatments.
| Comparison of treatments | Efficacy in patients with SHPT | Adverse events | References | ||
|---|---|---|---|---|---|
| Follow-up time | Target | Response rate | |||
| Etelcalcetide vs. Cinacalcet | 26 weeks | Reduction in PTH of more than 30% | 68.2% vs. 57.7% | Decreased blood calcium (68.9% vs. 59.8%) | (40) |
| 9 months | PTH level of 150–600 pg/mL | 48-62% vs. 40-47% | (23) | ||
| Evocalcet vs. Cinacalcet | 30 weeks | PTH level of 60-240 pg/mL | 72.7% vs. 76.7% | Gastrointestinal-related adverse events (18.6% vs. 32.8%) | (29) |
| sPTX vs. tPTX-AT | 6 months | PTH level | 270.6 pg/mL vs. 320.9 pg/mL | Recurrent HPT (5.6% vs. 4%) Persistent HPT (21.6% vs. 16%) |
(41) |
| 6 months | PTH level of 15-65 pg/mL | 22.2% vs. 26.7% | Recurrent or persistent HPT (26% vs. 8.7%) | (42) | |
| sPTX vs. tPTX-45AT vs. tPTX-90AT | 12 months | PTH level of 100–600 pg/mL | 44% vs. 33% vs. 45% | Un-controlled HPT (20% vs. 0% vs. 0%) | (43) |